Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Return on Sales (2022 - 2025)

Bioregenx's Return on Sales history spans 4 years, with the latest figure at 2.64% for Q4 2025.

  • Quarterly results put Return on Sales at 2.64% for Q4 2025, up 3732.0% from a year ago — trailing twelve months through Dec 2025 was 0.83% (up 797.0% YoY), and the annual figure for FY2025 was 0.83%, up 902.0%.
  • Return on Sales for Q4 2025 was 2.64% at Bioregenx, down from 0.16% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.0% in Q3 2023 to a low of 39.96% in Q4 2024.
  • The 4-year median for Return on Sales is 0.64% (2024), against an average of 3.53%.
  • The sharpest move saw Return on Sales plummeted -3890bps in 2024, then surged 3732bps in 2025.
  • Year by year, Return on Sales stood at 0.62% in 2022, then plummeted by -71bps to 1.06% in 2023, then crashed by -3663bps to 39.96% in 2024, then soared by 93bps to 2.64% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 2.64%, 0.16%, and 0.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.